Inquiry Basket
Gemtuzumab ozogamicin is an ADC consisting of a derivative of calicheamicin linked to a humanized monoclonal IgG4 antibody directed against CD33. Gemtuzumab ozogamicin has been approved for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML).
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01592 | -- | $-- | Inquiry |
Gemtuzumab ozogamicin is an innovative targeted therapeutic agent primarily used in the treatment of acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. Gemtuzumab ozogamicin is classified as an antibody-drug conjugate (ADC), a novel class of therapeutics that combines the targeting capabilities of monoclonal antibodies with the cell-killing capacity of cytotoxic drugs. The unique mechanism of this drug involves the selective targeting of leukemia cells while minimizing damage to normal, healthy cells.
The drug is composed of two main parts: a monoclonal antibody directed against the CD33 antigen, and a potent cytotoxic agent called calicheamicin. CD33 is a sialic acid-dependent adhesion protein found on the surface of myeloid leukemia cells and certain other blood cells. The monoclonal antibody component of gemtuzumab ozogamicin binds specifically to the CD33 antigen, allowing for precise targeting of cells that express this protein. Once the antibody binds to the leukemia cell, the drug is internalized into the cell where the cytotoxic agent, calicheamicin, is released. Calicheamicin then induces double-stranded DNA breaks, leading to cell cycle arrest and apoptotic cell death.
Gemtuzumab ozogamicin has shown efficacy in patients with newly diagnosed as well as relapsed or refractory AML. Its use is particularly beneficial in patients whose leukemia cells express the CD33 antigen. It is often used in combination with other chemotherapy agents or as a stand-alone therapy, depending on the specific clinical scenario, including factors such as patient age, cytogenetic profile, and overall health status.
One of the critical advantages of gemtuzumab ozogamicin is its targeted approach, which helps in reducing some of the side effects typically associated with conventional chemotherapy. However, it is not without its own risks, with potential side effects including infusion-related reactions, liver toxicity, and myelosuppression. As with any cancer therapy, careful patient selection and monitoring are essential to maximize therapeutic benefits and minimize adverse effects.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
